Abstract
Introduction

44
Streptococcus pneumoniae is the most common bacterial cause of 45 respiratory tract infections (RTI). Ciprofloxacin, the first fluoroquinolone to be 46 used to treat lower respiratory tract infections (LRTIs)(29), demonstrates poor 47 potency against S. pneumoniae and its introduction was associated with the 48 rapid emergence of resistance in pneumococci (5, 6, 9, 16, 26, 29) . by all sterile site isolates of S. pneumoniae. All laboratories were asked to 69 provide the date of collection, source of specimen, and patient age and gender.
70
In metropolitan Toronto and Peel Region (population: 3.5 The prevalence of isolates resistant to oral penicillin increased from 5.7% 
244
However, in multivariable analysis adjusted for the age of the patient, the source 245 of the specimen and whether or not the isolate was a serotype included in the 7-246 valent conjugate vaccine, there was no increase the prevalence of mutations 247 over the decade of surveillance.
248
The first pneumococcal isolate with a mutation in the QRDR of gyrA only levofloxacin at a dose of 500 mg once a day will just achieve it, and moxifloxacin 283 and gatifloxacin used at recommended daily doses, will achieve AUC/MIC ratios 
